<DOC>
	<DOCNO>NCT00004086</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate cancer cell either kill deliver cancer kill substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody plus combination chemotherapy peripheral stem cell transplantation treat patient recurrent B-cell cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody , Combination Chemotherapy , Peripheral Stem Cell Transplantation Treating Patients With Recurrent Refractory B-Cell Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity yttrium Y 90 humanize anti-CD22 LL2 ( Y90 MOAB hLL2 ) combination salvage chemotherapy autologous peripheral blood stem cell rescue patient recurrent refractory B-cell malignancy . II . Study effect chemotherapy uptake Y90 MOAB hLL2 tumor site normal organ pretherapy image use indium In 111 humanized LL2 intratherapy imaging . III . Determine extent duration tumor response patient receive regimen . OUTLINE : This dose escalation study yttrium Y 90 humanize anti-CD22 monoclonal antibody LL2 ( Y90 MOAB hLL2 ) . Patients receive filgrastim ( G-CSF ) subcutaneously daily 5 day undergo harvest peripheral blood stem cell ( PBSC ) 2 consecutive day . If adequate number CD34+ cell harvest , autologous bone marrow may use . Chemotherapy-induced mobilization filgrastim allow . Patients undergo pretherapy image indium In 111 humanized LL2 ( In111 hLL2 ) 40 minute day -7 . Patients receive Y90 MOAB hLL2 40 minute day 0 plus In111 hLL2 , follow Y90 MOAB hLL2 alone day 3 . Patients receive ifosfamide IV 1 hour , cisplatin IV 2 hour , cytarabine IV 2 hour day 1 4 . Oral etoposide give daily day 1-7 . PBSC bone marrow reinfused day 9-14 , depend MOAB clearance . Cohorts 3-6 patient receive escalate dos Y90 MOAB hLL2 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow weekly 2 month , monthly 6 month , every 6 month 5 year . PROJECTED ACCRUAL : Approximately 15-24 patient accrue study within 2-2.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm recurrent refractory Bcell malignancy fail least one standard therapy Stage II IV nonHodgkin 's lymphoma Bcell chronic lymphocytic leukemia , hairy cell leukemia , Waldenstrom 's macroglobulinemia allow : Autologous bone marrow peripheral blood stem cell ( PBSC ) great 5 % tumor involvement available Estimated radiation dose marrow great 3,000 cGy ( bone marrow involvement great 25 % allow provided stem cell contamination predict marrow radiation dos cite cut value ) At least 1 confirmed site tumor target pretherapy indium In 111 humanized LL2 Autologous peripheral blood stem cell ( PBSC ) bone marrow available No active brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2 mg/dL Renal : Creatinine le 1.5 time upper limit normal Cardiovascular : Cardiac ejection fraction great 50 % Pulmonary : DLCO great 60 % predict Forced vital capacity great 60 % predict Other : No severe anorexia , nausea , vomit HIV negative No prisoner No concurrent significant medical complication would preclude study compliance Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Prior low dose radioimmunotherapy allow Chemotherapy : No prior high dose chemotherapy PBSC rescue At least 4 week since prior chemotherapy recover Endocrine therapy : At least 2 week since prior corticosteroid recover Radiotherapy : Prior low dose radioimmunotherapy allow Prior radiotherapy le 35 % red marrow allow At least 4 week since prior radiotherapy index lesion Surgery : At least 4 week since major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>